$4515 | Single User
$5910 | Five User License
$7800 | Enterprise License

Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron and Others) - Global Opportunities and Forecast 2014-2022 [Report Updated: 13-01-2017]

Published by Allied Market Research: 13 Jan 2017 | 103426 | In Stock

Introduction

Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer.nnThe global Chemotherapy-induced Nausea and Vomiting market was valued at ,663 million in 2015, and is estimated to reach , 659 million by 2022, registering a CAGR of 7.1% during the forecast period. At present, pharmaceutical companies are increasingly investing in the further discovery of CINV drugs through focused clinical research studies. Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016 approximately 1.6 million new cases of cancer will be diagnosed with breast, lung and bronchus cancer as most common along all the types in addition to existing number of cancer patients.nnThe global CINV market is segmented into patient pool type and geography. The patient pool type is segmented into namely Aloxi (palonosetron), Kytril Generic (Granisetron), Emend (aprepitant), Netupitant-Palonosetron FDC and Others. Among the segments, the Netupitant Palonosetron market is expected to witness the fastest growth, globally during the forecast period 2016-2022.nnBased on geography, the global CINV market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share (nearly half) in the global chemotherapy-induced nausea and vomiting market in 2015 due to growth in demand for CINV drugs due to the rise in number of patients undergoing chemotherapy, introduction of novel delivery methods to improve patient compliance. However, Asian region is expected to grow at a fastest CAGR during the forecast period, owing to large CINV patient pool and huge demand for the Netupitant–Palonosetron from these patients. Netupitant - Palonosetron is one of the first forms of fixed dose combination, which is approved for treating chemotherapy-induced nausea and vomiting that is likely to drive this market in the near future.nnKEY BENEFITSnnnnThe study provides in-depth analysis of the CINV market along with the current trends and future estimations to elucidate the imminent investment pockets.nnThe study provides analysis of key market dynamics, which influence the adoption of CINV drugsnnThe report provides a quantitative analysis for the period of 2014–2022 to enable stakeholders to capitalize on the prevailing opportunities in the industry.nnExtensive analysis of the global market helps understand cancer inducing Nausea and vomiting drugs developed and marketed by the key companies.nnCompetitive intelligence of market players highlights the business practices and trends across various regions.nnnKEY MARKET SEGMENTS:nnPatient Pool TypennnnAloxi, KytrilnnEmendnnNetupitant-PalonosetronnnOthersnnnBy GeographynnnnNorth AmericannnnnnUSnnnCanadannnMexiconnnnnnEuropennnnnGermanynnnFrancennnUKnnnRest of EuropennnnnnAsia-PacificnnnnnChinannnJapannnnRest of Asia-PacificnnnnnnLAMEAnnnnnLatin AmericannnMiddle EastnnnAfricannnnn

LIST OF KEY PLAYERS PROFILED IN THE REPORTnnnnGlaxoSmithKline plcnnHelsinn Holding S.A.nnHeron Therapeutics, Inc.nnMerck & Co., Inc.nnTesaro, Incn

Table of Contents
for Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron and Others) - Global Opportunities and Forecast 2014-2022 [Report Updated: 13-01-2017]

  • Chapter: 1 INTRODUCTION

    1.1 Report Description
    1.2 Key Benefits
    1.3 Key Market Segments
    1.4 Research Methodology

    1.4.1 Secondary Research
    1.4.2 Primary Research
    1.4.3 Analyst Tools and Models

    Chapter: 2 EXECUTIVE SUMMARY

    2.1 CXO Perspective

    Chapter: 3 MARKET OVERVIEW

    3.1 Market Definition and Scope
    3.2 Key Findings

    3.2.1 Top Impacting Factors
    3.2.2 Top Investment Pockets

    3.3 Porters Five Force Analysis
    3.4 Drivers

    3.4.1 Growing Number of patients undergoing Chemotherapy
    3.4.2 Growing research and development efforts in order to discover a universal antiemetic therapy
    3.4.3 Introduction of novel delivery methods to improve patient compliance.
    3.4.4 Advancements in technology to discover new potential drug targets

    3.5 Restrains

    3.5.1 Increasing side effects of CINV drugs
    3.5.2 High cost associated with the new drug discovery and in developing regions.

    3.6 Opportunities

    3.6.1 Efficacy of combination therapy is expected to improve.
    3.6.2 Improved quality of life for patients with cancer.

    3.7 Market Trends

    Chapter: 4 CINV MARKET BY PATIENT POOL

    4.1 Overview
    4.2 Netupitant-Palonosetron FDC

    4.2.1 Key market trends
    4.2.2 Key growth factors & opportunities
    4.2.3 Market size & forecasts

    4.3 Aloxi (palonosetron)

    4.3.1 Key market trends
    4.3.2 Key growth factors & opportunities
    4.3.3 Market size & forecasts

    4.4 Kytril Generic (Granisetron)

    4.4.1 Key market trends
    4.4.2 Key growth factors & opportunities
    4.4.3 Market size & forecasts

    4.5 Emend (aprepitant)

    4.5.1 Key market trends
    4.5.2 Key growth factors & opportunities
    4.5.3 Market size & forecasts

    Chapter: 5 CINV MARKET BY GEOGRAPHY

    5.1 North America

    5.1.1 Key Market Trends
    5.1.2 Key Growth Factors and Opportunities
    5.1.3 Market Size and Forecast

    5.2 Europe

    5.2.1 Key Market Trends
    5.2.2 Key Growth Factors and Opportunities
    5.2.3 Market Size and Forecast

    5.3 Asia-Pacific

    5.3.1 Key Market Trends
    5.3.2 Key Growth Factors and Opportunities
    5.3.3 Market Size and Forecast

    5.4 Latin America, Middle East and Africa (LAMEA)

    5.4.1 Key Market Trends
    5.4.2 Key Growth Factors and Opportunities
    5.4.3 Market Size and Forecast

    Chapter: 6 COMPANY PROFILES

    6.1 Helsinn Holding S.A.

    6.1.1 Company Overview
    6.1.2 Key Strategies and Developments
    6.1.3 SWOT Analysis

    6.2 Heron Therapeutics, Inc.

    6.2.1 Company Overview
    6.2.2 Business Performance
    6.2.3 Key Strategies and Developments
    6.2.4 SWOT Analysis

    6.3 Merck & Co., Inc

    6.3.1 Company Overview
    6.3.2 Business Performance
    6.3.3 Key Strategies and Developments
    6.3.4 SWOT Analysis

    6.4 GlaxoSmithKline plc

    6.4.1 Company Overview
    6.4.2 Business Performance
    6.4.3 Key Strategies and Developments
    6.4.4 Key Strategies and Developments
    6.4.5 SWOT Analysis

    6.5 Cadila Pharmaceuticals Limited

    6.5.1 Company Overview
    6.5.2 Business Performance
    6.5.3 Key Strategies and Developments
    6.5.4 Key Strategies and Developments
    6.5.5 SWOT Analysis

    6.6 Amneal Pharmaceuticals

    6.6.1 Company Overview
    6.6.2 Business Performance
    6.6.3 Key Strategies and Developments
    6.6.4 Key Strategies and Developments
    6.6.5 SWOT Analysis

    6.7 Kyowa Kirin, Inc.

    6.7.1 Company Overview
    6.7.2 Business Performance
    6.7.3 Key Strategies and Developments
    6.7.4 Key Strategies and Developments
    6.7.5 SWOT Analysis

    6.8 Acacia Pharma

    6.8.1 Company Overview
    6.8.2 Business Performance
    6.8.3 Key Strategies and Developments
    6.8.4 Key Strategies and Developments
    6.8.5 SWOT Analysis

    6.9 Insys Therapeutics, Inc

    6.9.1 Company Overview
    6.9.2 Business Performance
    6.9.3 Key Strategies and Developments
    6.9.4 Key Strategies and Developments
    6.9.5 SWOT Analysis

    6.10 Tesaro, Inc.

    6.10.1 Company Overview
    6.10.2 Business Performance
    6.10.3 Key Strategies and Developments
    6.10.4 Key Strategies and Developments
    6.10.5 SWOT Analysis

    *Details on financial performance, strategic moves and developments and SWOT analysis may not be captured for unlisted companies.

    List of Figures

    FIG. 1 TOP IMPACTING FACTORS
    FIG. 2 TOP INVESTMENT POCKETS
    FIG. 3 PORTERS FIVE FORCES ANALYSIS OF LITHIUM-ION BATTERY MARKET
    FIG. 4 WORLD CINV MARKET BY TYPE, 2015(PIE CHART OF GLOBAL NUMBERS BY TYPE)
    FIG. 5 WORLD CINV MARKET BY GEOGRAPHY, 2015(PIE CHART OF GLOBAL NUMBERS BY GEOGRAPHY)
    FIG. 6 NET SALES OF HERON THERAPEUTICS, INC., 2013-2015 ($MILLION)
    FIG. 7 NET SALES OF HERON THERAPEUTICS, INC., BY SEGMENT (%), 2015
    FIG. 8 NET SALES OF HERON THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015
    FIG. 10 NET SALES OF MERCK & CO., INC, 2013-2015 ($MILLION)
    FIG. 11 NET SALES OF MERCK & CO., INC., BY GEOGRAPHY (%), 2015
    FIG. 11 NET SALES OF MERCK & CO., INC., BY SEGMENT (%), 2015
    FIG. 12 NET SALES OF GLAXOSMITHKLINE PLC ., 2013-2015 ($MILLION)
    FIG. 13 NET SALES OF GLAXOSMITHKLINE PLC, BY SEGMENT (%), 2015
    FIG. 14 NET SALES OF GLAXOSMITHKLINE PLC, BY GEOGRAPHY (%), 2015
    FIG. 18 NET SALES OF KYOWA KIRIN, INC., 2013-2015 ($MILLION)
    FIG. 13 NET SALES OF KYOWA KIRIN, INC., BY SEGMENT (%), 2015
    FIG. 14 NET SALES OF KYOWA KIRIN, INC., BY GEOGRAPHY (%), 2015
    FIG. 22 REVENUE OF INSYS THERAPEUTICS, INC., 2013-2015 ($MILLION)
    FIG. 13 NET SALES OF INSYS THERAPEUTICS, INC., BY SEGMENT (%), 2015
    FIG. 14 NET SALES OF INSYS THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015
    FIG. 22 REVENUE OF TESARO, INC, 2013-2015 ($MILLION)
    FIG. 13 NET SALES OF TESARO, INC, BY SEGMENT (%), 2015
    FIG. 14 NET SALES OF TESARO, INC, BY GEOGRAPHY (%), 2015

    List of Tables

    TABLE 1 WORLD CINV MARKET BY PATIENT POOL(NETUPITANT-PALONOSETRON FDC) MARKET, ($MILLION), GROWTH (%)2014-2022
    TABLE 2 WORLD CINV MARKET BY PATIENT POOL( ALOXI) , ($MILLION), GROWTH (%)2014-2022
    TABLE 3 WORLD CINV MARKET BY PATIENT POOL(KYTRIL GENERIC ) , ($MILLION), GROWTH (%)2014-2022
    TABLE 4 WORLD CINV MARKET BY PATIENT POOL(EMEND ) , ($MILLION), GROWTH (%)2014-2022
    TABLE 5 NORTH AMERICA CINV MARKET, ($MILLION), GROWTH (%)2014-2022
    TABLE 6 EUROPE CINV MARKET, ($MILLION), GROWTH (%)2014-2022
    TABLE 7 ASIA CINV MARKET, ($MILLION), GROWTH (%)2014-2022
    TABLE 8 LAMEA CINV MARKET, ($MILLION), GROWTH (%)2014-2022
    TABLE 9 HELSINN HOLDING S.A.COMPANY SNAPSHOT
    TABLE 9 HELSINN HOLDING S.A.OPERATING SEGMENTS
    TABLE 10 HERON THERAPEUTICS, INC. COMPANY SNAPSHOT
    TABLE 11 HERON THERAPEUTICS, INC.OPERATING SEGMENTS
    TABLE 12 MERCK & CO., INC. COMPANY SNAPSHOT
    TABLE 13 MERCK & CO., INC.OPERATING SEGMENTS
    TABLE 14 GLAXOSMITHKLINE PLC COMPANY SNAPSHOT
    TABLE 15 GLAXOSMITHKLINE PLC OPERATING SEGMENTS
    TABLE 16 CADILA PHARMACEUTICALS LIMITED COMPANY SNAPSHOT
    TABLE 17 CADILA PHARMACEUTICALS LIMITED OPERATING SEGMENTS
    TABLE 18 AMNEAL PHARMACEUTICALS COMPANY SNAPSHOT
    TABLE 19 AMNEAL PHARMACEUTICALS OPERATING SEGMENTS
    TABLE 20 KYOWA KIRIN, INC. COMPANY SNAPSHOT
    TABLE 21 KYOWA KIRIN, INC. OPERATING SEGMENTS
    TABLE 22 ACACIA PHARMA COMPANY SNAPSHOT
    TABLE 23 ACACIA PHARMA OPERATING SEGMENTS
    TABLE 24 INSYS THERAPEUTICS, INC. COMPANY SNAPSHOT
    TABLE 25 INSYS THERAPEUTICS, INC. OPERATING SEGMENTS
    TABLE 26 TESARO, INC. COMPANY SNAPSHOT
    TABLE 27 TESARO, INC. OPERATING SEGMENTS

Additional Details

Publisher

Allied Market Research

Publisher Information

Reference

103426 | LI 171846

Number of Pages

70

Report Format

PDF

Allied Market Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Latin America Infusion Pump Market by Product (Volumetric, Syringe, Feeding, Insulin, PCA Pump), Application (Chemotherapy, Gastroenterology, Diabetes, Pain Management), Setting (Hospital, Ambulatory Centers), Accessories - Forecast to 2021
The Latin American infusion pumps and accessories market is estimated to reach USD 671.9 million by ...
20 Sep 2016 by MarketsandMarkets USD $5,650 More Info
Chemotherapy Induced Pain Global Clinical Trials Review, H1, 2016
Chemotherapy Induced Pain Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial ...
29 Jun 2016 by Global Data USD $2,500 More Info
Chemotherapy Induced Neutropenia Global Clinical Trials Review, H1, 2016
Chemotherapy Induced Neutropenia Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical...
15 Jun 2016 by Global Data USD $2,500 More Info
Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016
Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016SummaryGlobalData'...
15 Jun 2016 by Global Data USD $2,500 More Info
Chemotherapy Induced Anemia Global Clinical Trials Review, H1, 2016
Chemotherapy Induced Anemia Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical tria...
15 Jun 2016 by Global Data USD $2,500 More Info
Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2016
Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2016SummaryGlobalData's ...
30 Apr 2016 by Global Data USD $2,500 More Info
Infusion Pump Market - by Product (Volumetric, Syringe, Feeding, Insulin, PCA Pump), by Application (Chemotherapy, Gastroenterology, Diabetes, Pain Management), by End User (Hospital, Home Care, Ambulatory Surgery Centers) - Global Forecast to 2020
The global infusion pumps and accessories market is expected to grow at a CAGR of 5.8% during the fo...
11 Jan 2016 by MarketsandMarkets USD $4,650 More Info
Chemotherapy Induced Anemia Global Clinical Trials Review, H2, 2015
Chemotherapy Induced Anemia Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical tria...
25 Nov 2015 by Global Data USD $2,500 More Info
Physician Views: Can Astellas, Medivation's Xtandi meet expectations in pre-chemotherapy prostate cancer?
Scope Having secured approval for the treatment of pre-chemotherapy prostate cancer patients earlier...
25 Sep 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?
ScopeThe prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medi...
01 Oct 2013 by FirstWord Pharma USD $695 More Info

This report is published by Allied Market Research

Download Free Report Summary PDF

Global Chemotherapy-induced Nausea and Vomiting (CINV) Market (Patient Pool Type: Aloxi, Kytril, Emend, and Netupitant-Palonosetron and Others) - Global Opportunities and Forecast 2014-2022 [Report Updated: 13-01-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data